Histopathological evaluation of the resected specimen revealed a 3 cm in diameter extra-adrenal paraganglioma, a 2.5 cm in diameter left adrenal and a 1 cm in diameter right adrenal ...
The 2004 WHO classification of endocrine tumors defines pheochromocytoma as a tumor arising from catecholamine-producing chromaffin cells in the adrenal ... paraganglioma. Closely related tumors ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...
Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...
The panel of experts at the ISP felt strongly that localization of pheochromocytoma or paraganglioma should ... of the relationship between adrenal and extra-adrenal tumor locations according ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback